Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | VDR | P11473 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23643337 | 0.81 | RECQL (0.35) | RECQLGAAVDRCA12CA1 | |
| SCHEMBL19323273 | 0.79 | HPGD (0.42) | MEN1KMT2ARECQLGAACYP2C9 | |
| SCHEMBL16388489 | 0.79 | RECQL (0.34) | RECQLGAAVDR | |
| SCHEMBL3467454 | 0.79 | ALDH1A1 (0.44) | MEN1KMT2ARECQLGAAVDR | |
| SCHEMBL12617509 | 0.79 | TERT (0.38) | RECQLGAAVDRCYP1A2CA12 | |
| SCHEMBL21850085 | 0.77 | CA1 (0.34) | RECQLVDRCA1CA2 | |
| SCHEMBL17721379 | 0.77 | MEN1 (0.54) | MEN1KMT2ARECQLCYP2C9SMN1; SMN2 | |
| SCHEMBL8056854 | 0.77 | RECQL (0.33) | RECQLVDR | |
| SCHEMBL21099972 | 0.76 | RECQL (0.55) | MEN1KMT2APSMB5RECQLGAA | |
| SCHEMBL3715221 | 0.76 | RECQL (0.50) | RECQLGAASMN1; SMN2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190076405-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASASIS OF CANCER CELLS | EyePoint Pharmaceuticals, Inc. | 2019-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190076405-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASASIS OF CANCER CELLS | TSG101, MMP8, EPCAM | MEN1 140/4885KMT2A 3918/4885PSMB5 4154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.